Blog
RSS FeedPosted by Michael Wonder on 28 Jan 2022
Pfizer's COVID-19 vaccine (Comirnaty) provisionally approved for use as a booster in individuals aged 16-17 years old
28 January 2022 - The Therapeutic Goods Administration has provisionally approved the Pfizer COVID-19 vaccine, Comirnaty for use as a ...
Posted by Michael Wonder on 27 Jan 2022
Moderna aims to deliver Omicron COVID-19 vaccine by September
27 January 2022 - A COVID-19 booster shot, targeted specifically at the Omicron variant, is expected to be delivered by ...
Posted by Michael Wonder on 27 Jan 2022
COVID-19: EMA recommends conditional marketing authorisation for Paxlovid
27 January 2022 - The EMA’s CHMP has recommended granting a conditional marketing authorisation for the oral antiviral medicine Paxlovid ...
Posted by Michael Wonder on 27 Jan 2022
COVID-19 vaccine weekly safety report (27 January 2022)
27 January 2022 - To 23 January 2022, the TGA has received 431 reports which have been assessed as likely to ...
Posted by Michael Wonder on 26 Jan 2022
Pfizer pushes to intervene in lawsuit seeking COVID vaccine information from FDA
27 January 2022 - Pfizer wants to intervene in a Texas federal lawsuit seeking information from the U.S. FDA used ...
Posted by Michael Wonder on 26 Jan 2022
PHARMAC confirms access criteria for COVID-19 treatments
26 January 2022 - PHARMAC has today confirmed the access criteria for two COVID-19 treatments – baricitinib and casirivimab with ...
Posted by Michael Wonder on 24 Jan 2022
Chugai’s Actemra approved for additional indication of SARS-CoV-2 pneumonia in Japan
21 January 2022 - The approval is based on the results of several clinical studies in hospitalised patients with COVID-19. ...
Posted by Michael Wonder on 24 Jan 2022
Novavax COVID-19 vaccine to be available in coming weeks
24 January 2022 - Australians aged 18+ will now have access to a fourth COVID-19 vaccine, Nuvaxovid (Novavax) in coming weeks, ...
Posted by Michael Wonder on 24 Jan 2022
FDA considers limiting authorisation of certain monoclonal antibody treatments
23 January 2022 - Federal regulators are considering limiting the authorisation of certain monoclonal antibody treatments that have not proved ...
Posted by Michael Wonder on 23 Jan 2022
ATAGI statement on the use of Novavax COVID-19 vaccine (Nuvaxovid)
24 January 2022 - ATAGI recommends that Novavax COVID-19 vaccine can be used for the primary course of COVID-19 vaccination ...
Posted by Michael Wonder on 23 Jan 2022
Pharmacists struggle to meet demand for free COVID test kits amid stock shortage
23 January 2022 - Chemists across the country say they do not have enough rapid antigen tests to start handing ...
Posted by Michael Wonder on 22 Jan 2022
COVID-19: early access granted to Paxlovid as a curative treatment
21 January 2022 - In the context of very high circulation of SARS-CoV-2, the High Authority for Health (HAS) and the ...
Posted by Michael Wonder on 22 Jan 2022
COVID-19 vaccines and treatments: we must have raw data, now
19 January 2022 - Data should be fully and immediately available for public scrutiny ...
Posted by Michael Wonder on 22 Jan 2022
FDA takes actions to expand use of treatment for outpatients with mild to moderate COVID-19
21 January 2022 - Today, the U.S. FDA took two actions to expand the use of the antiviral drug Veklury (remdesivir) ...
Posted by Michael Wonder on 21 Jan 2022
International regulators’ recommendations on COVID-19 vaccines and the Omicron variant
21 January 2022 - International regulators have published a report today highlighting their discussions on the effectiveness of current vaccines against ...